Adverse Events and Safety of SARS-CoV-2 Vaccines: What’s New and What’s Next

Just over 1 year following rollout of the first vaccines for coronavirus disease 2019, 572 million doses have been administered in the United States. Compared with the number of vaccines administered, adverse effects such as anaphylaxis have been rare, and seemingly, the more serious the effect, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Corey, Kristen B., Koo, Grace, Phillips, Elizabeth J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Academy of Allergy, Asthma & Immunology 2022
Materias:
Review and Feature Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085443/
https://www.ncbi.nlm.nih.gov/pubmed/35550878
http://dx.doi.org/10.1016/j.jaip.2022.04.035
_version_ 1784703818848534528
author Corey, Kristen B.
Koo, Grace
Phillips, Elizabeth J.
author_facet Corey, Kristen B.
Koo, Grace
Phillips, Elizabeth J.
author_sort Corey, Kristen B.
collection PubMed
description Just over 1 year following rollout of the first vaccines for coronavirus disease 2019, 572 million doses have been administered in the United States. Compared with the number of vaccines administered, adverse effects such as anaphylaxis have been rare, and seemingly, the more serious the effect, the rarer the occurrence. Despite these adverse effects, there are few, if any, true contraindications to coronavirus disease 2019 vaccination and most individuals recover without further sequelae. This review provides guidance for the allergist/immunologist regarding appropriate next steps based on patient’s known allergy history or adverse reaction after receipt of coronavirus disease 2019 vaccine to assist in safe global immunization.
format Online
Article
Text
id pubmed-9085443
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Academy of Allergy, Asthma & Immunology
record_format MEDLINE/PubMed
spelling pubmed-90854432022-05-10 Adverse Events and Safety of SARS-CoV-2 Vaccines: What’s New and What’s Next Corey, Kristen B. Koo, Grace Phillips, Elizabeth J. J Allergy Clin Immunol Pract Review and Feature Article Just over 1 year following rollout of the first vaccines for coronavirus disease 2019, 572 million doses have been administered in the United States. Compared with the number of vaccines administered, adverse effects such as anaphylaxis have been rare, and seemingly, the more serious the effect, the rarer the occurrence. Despite these adverse effects, there are few, if any, true contraindications to coronavirus disease 2019 vaccination and most individuals recover without further sequelae. This review provides guidance for the allergist/immunologist regarding appropriate next steps based on patient’s known allergy history or adverse reaction after receipt of coronavirus disease 2019 vaccine to assist in safe global immunization. American Academy of Allergy, Asthma & Immunology 2022-09 2022-05-10 /pmc/articles/PMC9085443/ /pubmed/35550878 http://dx.doi.org/10.1016/j.jaip.2022.04.035 Text en © 2022 American Academy of Allergy, Asthma & Immunology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review and Feature Article
Corey, Kristen B.
Koo, Grace
Phillips, Elizabeth J.
Adverse Events and Safety of SARS-CoV-2 Vaccines: What’s New and What’s Next
title Adverse Events and Safety of SARS-CoV-2 Vaccines: What’s New and What’s Next
title_full Adverse Events and Safety of SARS-CoV-2 Vaccines: What’s New and What’s Next
title_fullStr Adverse Events and Safety of SARS-CoV-2 Vaccines: What’s New and What’s Next
title_full_unstemmed Adverse Events and Safety of SARS-CoV-2 Vaccines: What’s New and What’s Next
title_short Adverse Events and Safety of SARS-CoV-2 Vaccines: What’s New and What’s Next
title_sort adverse events and safety of sars-cov-2 vaccines: what’s new and what’s next
topic Review and Feature Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085443/
https://www.ncbi.nlm.nih.gov/pubmed/35550878
http://dx.doi.org/10.1016/j.jaip.2022.04.035
work_keys_str_mv AT coreykristenb adverseeventsandsafetyofsarscov2vaccineswhatsnewandwhatsnext
AT koograce adverseeventsandsafetyofsarscov2vaccineswhatsnewandwhatsnext
AT phillipselizabethj adverseeventsandsafetyofsarscov2vaccineswhatsnewandwhatsnext

Ejemplares similares